Labcorp Holdings Inc. (LH)
Labcorp Holdings Inc. (LH) EBITDA
The ebitda for Labcorp Holdings Inc. (LH) is $2.01 Billion with a year-over-year change of +11.12%. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) measures a company's operating performance by removing non-cash charges and capital structure effects.
LH EBITDA Chart
LH EBITDA
$2.01B+156.46% 20Y
Zoom
Current EBITDA
$2.01B
$2.01 Billion
Year-over-Year Change
+11.12%
vs. $1.81B prior year
Historical Data
30
Years of data available
Annual EBITDA History
| Year | EBITDA | YoY Change | % Change |
|---|---|---|---|
| 2025 | $2.01B | +$201.40M | +11.12% |
| 2024 | $1.81B | +$461.90M | +34.23% |
| 2023 | $1.35B | $-605.00M | -30.96% |
| 2022 | $1.95B | $-1.72B | -46.84% |
| 2021 | $3.68B | +$424.90M | +13.07% |
| 2020 | $3.25B | +$1.13B | +53.60% |
| 2019 | $2.12B | +$52.30M | +2.53% |
| 2018 | $2.06B | +$218.80M | +11.85% |
| 2017 | $1.85B | +$36.20M | +2.00% |
| 2016 | $1.81B | +$232.80M | +14.76% |
| 2015 | $1.58B | +$401.20M | +34.13% |
| 2014 | $1.18B | $-62.90M | -5.08% |
| 2013 | $1.24B | $-21.40M | -1.70% |
| 2012 | $1.26B | +$79.00M | +6.69% |
| 2011 | $1.18B | $-8.30M | -0.70% |
| 2010 | $1.19B | +$48.40M | +4.24% |
| 2009 | $1.14B | +$105.10M | +10.15% |
| 2008 | $1.04B | +$45.30M | +4.57% |
| 2007 | $990.40M | +$137.30M | +16.09% |
| 2006 | $853.10M | +$68.30M | +8.70% |
| 2005 | $784.80M | $-5.40M | -0.68% |
| 2004 | $790.20M | +$121.80M | +18.22% |
| 2003 | $668.40M | +$114.10M | +20.58% |
| 2002 | $554.30M | +$82.70M | +17.54% |
| 2001 | $471.60M | +$131.90M | +38.83% |
| 2000 | $339.70M | +$105.50M | +45.05% |
| 1999 | $234.20M | +$22.40M | +10.58% |
| 1998 | $211.80M | +$194.30M | +1110.29% |
| 1997 | $17.50M | $-169.20M | -90.63% |
| 1996 | $186.70M | — | — |
Data as of Sunday, June 14, 2026
About Labcorp Holdings Inc.
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Adam H. Schechter